Incyte (INCY) Competitors $84.80 +0.90 (+1.07%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$85.02 +0.23 (+0.27%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, REGN, ALNY, BIIB, UTHR, NBIX, BMRN, EXEL, EXAS, and IONSShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Exact Sciences Ionis Pharmaceuticals AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Is ABBV or INCY more profitable? Incyte has a net margin of 18.99% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 699.66% 13.64% Incyte 18.99%21.99%14.43% Which has higher valuation and earnings, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B6.90$4.28B$2.10104.84Incyte$4.24B3.90$32.62M$4.4019.27 Which has more risk & volatility, ABBV or INCY? AbbVie has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Does the media prefer ABBV or INCY? In the previous week, AbbVie had 118 more articles in the media than Incyte. MarketBeat recorded 144 mentions for AbbVie and 26 mentions for Incyte. Incyte's average media sentiment score of 1.35 beat AbbVie's score of 1.02 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 94 Very Positive mention(s) 14 Positive mention(s) 16 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ABBV or INCY? 70.2% of AbbVie shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.3% of AbbVie shares are held by company insiders. Comparatively, 17.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ABBV or INCY? AbbVie presently has a consensus target price of $222.68, suggesting a potential upside of 1.15%. Incyte has a consensus target price of $82.53, suggesting a potential downside of 2.67%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 4 Strong Buy rating(s) 2.93Incyte 1 Sell rating(s) 10 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryAbbVie beats Incyte on 10 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.38B$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E Ratio19.2721.0377.1026.52Price / Sales3.90249.02451.8387.93Price / Cash151.5545.4837.2260.63Price / Book4.749.5613.846.31Net Income$32.62M-$53.02M$3.29B$271.37M7 Day Performance-1.59%-1.58%-0.75%0.57%1 Month Performance-0.14%2.82%3.84%6.20%1 Year Performance30.12%9.34%84.93%28.33% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7342 of 5 stars$84.80+1.1%$82.53-2.7%+27.7%$16.38B$4.24B19.272,617Positive NewsShort Interest ↓ABBVAbbVie4.7354 of 5 stars$209.97-1.2%$214.95+2.4%+13.8%$375.50B$56.33B99.9955,000Trending NewsAnalyst ForecastAnalyst RevisionREGNRegeneron Pharmaceuticals4.756 of 5 stars$558.44-2.6%$817.67+46.4%-48.9%$60.77B$14.20B14.0715,106Trending NewsShort Interest ↑ALNYAlnylam Pharmaceuticals3.8942 of 5 stars$455.03+0.7%$417.38-8.3%+64.6%$59.25B$2.25B-184.222,230Positive NewsAnalyst ForecastBIIBBiogen4.6939 of 5 stars$141.35+0.5%$185.74+31.4%-26.9%$20.62B$9.68B13.517,605Positive NewsUTHRUnited Therapeutics4.7293 of 5 stars$394.62-1.5%$429.62+8.9%+17.0%$18.07B$2.88B15.401,305Positive NewsInsider TradeNBIXNeurocrine Biosciences4.6693 of 5 stars$143.80-0.2%$160.00+11.3%+16.7%$14.29B$2.36B42.541,800Positive NewsBMRNBioMarin Pharmaceutical4.9593 of 5 stars$56.38-2.4%$92.04+63.3%-22.9%$11.09B$2.85B16.733,040Short Interest ↑EXELExelixis4.6427 of 5 stars$37.69-0.5%$44.06+16.9%+46.5%$10.20B$2.17B18.121,147Trending NewsAnalyst DowngradeEXASExact Sciences4.7727 of 5 stars$53.89+0.1%$67.05+24.4%-23.0%$10.19B$2.76B-9.927,000Positive NewsShort Interest ↓Analyst RevisionIONSIonis Pharmaceuticals3.8233 of 5 stars$61.00-0.4%$67.88+11.3%+47.4%$9.76B$705M-33.151,069Insider TradeAnalyst Revision Related Companies and Tools Related Companies AbbVie Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Exact Sciences Competitors Ionis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
